


## 116P MOTILIN MEDIATES VASOCONSTRICTION IN HUMAN CORONARY ARTERY *IN VITRO*

J. J. Maguire, R. E. Kuc & A. P. Davenport. Clinical Pharmacology Unit, University of Cambridge, Level 6 Centre for Clinical Investigation, Box 110 Addenbrooke's Hospital, Cambridge. CB2 2QQ, UK

Motilin, a 22 amino acid peptide originally isolated from the gastrointestinal tract, has been paired with the orphan G-protein coupled receptor GPR38 (Feighner *et al.*, 1999). We have demonstrated the presence of specific motilin binding sites in the human cardiovascular system, including the vascular smooth muscle layer of arteries and veins (Kuc *et al.*, 2003). Vascular responses to motilin have been observed, with a depressor effect seen in pithed rat, *in vivo* (Eimerl *et al.*, 1985) and endothelium-dependent relaxation of porcine coronary artery *in vitro* (Higuchi *et al.*, 1994). Direct effects on vascular smooth muscle have not been reported. Therefore our aim was to determine the action of motilin on endothelium-denuded human coronary artery *in vitro*.

Human coronary artery (CA) was obtained, with ethical approval, from 12 patients transplanted for cardiomyopathy (n=8, 2 female, 6 male; 33-54 years), ischaemic heart disease (n=1, male; 44 years) or lung disease (n=2, 2 female 24 and 35 years). Rings (4mm) of endothelium-denuded CA were set up in 5ml organ baths, containing Krebs' solution (37°C), for isometric tension recordings. Following normalisation to establish optimal basal tension, cumulative concentration-response curves were constructed to endothelin-1 (ET-1) and motilin ( $1 \times 10^{-10}$ - $3 \times 10^{-7}$ M). Experiments were terminated by the addition of 100mM KCl to determine the maximum possible response and agonist responses were expressed as a percentage of this maximum. Data were analysed using a four parameter logistic equation (FigP, Biosoft, Cambridge, UK) to determine  $pD_2$  and  $E_{max}$  values. Data are the mean  $\pm$  s.e.mean and n-values are the number of patients.



$19.8 \pm 5.9\%$  (n=6) (Fig. 1).

ET-1 and motilin in human coronary artery.

We have demonstrated, that in common with other orphan receptor ligands such as urotensin-II and neuromedin U-25, motilin is a potent, low efficacy vasoconstrictor of human coronary artery and we speculate that vascular motilin receptors, present on the smooth muscle, may be activated either by motilin circulating in the plasma or released locally from nerve terminals.

Eimerl, J. *et al.*, (1985). *Neuropeptides*, 6, 157-165

Feighner, S.D. *et al.*, (1999). *Science*, 284, 2184-2188

Higuchi, Y. *et al.*, (1994). *Biochem. Biophys. Res. Commun.*, 202, 346-353

Kuc, R.E. *et al.*, (2003). *Br. J. Pharmacol.*, 138, 165P

*Supported by grants from the British Heart Foundation*

ET-1 contracted all arteries tested with a  $pD_2$  value of  $7.77 \pm 0.13$  and  $E_{max}$  of  $75.3 \pm 6.4\%$  KCl (n=11). Responses to motilin were more varied. Motilin was without effect in arteries from 3 patients and produced responses of  $<5\%$  KCl in arteries from 3 patients. Vasoconstrictor responses of between  $E_{max}$  10-53% KCl were obtained in arteries from 6 patients with  $pD_2$  value of  $7.97 \pm 0.23$  and mean  $E_{max}$  of